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Background
Malignant cells may be recognised by T cells binding cell
surface Class I HLA (Human Leukocyte Antigen)-peptide
complexes presenting disease-associated epitopes. Many
cancer patients have been shown to generate CD8 cyto-
toxic T cell responses to tumour-associated antigens.
However, this is often insufficient for the immune system
to clear tumours, resulting in the progression of cancer.
This is in part due to the low avidity of these T cells, as
well as the ability of cancer cells to develop escape
mechanisms to avoid destruction by T cells.
Methods
To overcome these issues, we have engineered novel, bi-
functional protein therapeutics termed ImmTACs
(Immune mobilising monoclonal TCR Against Cancer)
which re-direct the immune system to target and destroy
tumour cells with a high degree of potency and specificity.
An ImmTAC comprises a high affinity ‘monoclonal’ T cell
receptor (mTCR) targeting a cancer-associated HLA-pep-
tide complex, fused to an anti-CD3 scFv domain which
activates an anti-tumour T cell response.
Results
We have developed an integrated in-house process lead-
ing to the isolation of TCRs specific for validated cancer
epitopes forming the starting material for ImmTAC pro-
duction. The essential steps in this procedure are: antigen
selection, epitope identification, T cell cloning, TCR
isolation and binding to soluble peptide:MHC on the
Biacore. High affinity ImmTACs are then generated
through a process of affinity maturation.
Conclusions
The steps leading to the cloning of wild type TCRs are
presented here, together with exemplary data to illus-
trate the successful isolation of TCRs resulting from this
process.
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